ACTU Stock Forecast: Actuate Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Actuate Therapeutics, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 39 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Actuate Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (83): Sales and profits are climbing, and climbing faster than before.
Momentum (2): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ACTU stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ACTU, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $15 → $10 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 30 July 2026 | Rodman & Renshaw | Initiates | Buy | $6.00 |
| 18 May 2026 | HC Wainwright & Co. | Reiterates | Buy | $15 |
| 22 Apr 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Apr 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Nov 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 23 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 26 Aug 2025 | B. Riley Securities | Initiates | Buy | — |
| 18 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 Mar 2025 | HC Wainwright & Co. | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ACTU.
This page is one stock. Monday covers all of them.
ACTU appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ACTU vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Actuate Therapeutics, Inc. returned −96.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ACTU analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 0.7×
- EV / EBITDA
- —
Cheaper than 82% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −280.5%
- Return on assets
- −213.4%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Actuate Therapeutics, Inc. has a market value of $13.6M and an enterprise value of $2.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$20.5M.
Free cash flow in the twelve months to 30 June 2026: −$19.8M.
Actuate Therapeutics, Inc. employs 12 people.
Data provided by Twelve Data
ACTU and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ACTU’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Actuate Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ACTU
What is the ACTU stock price forecast for 2026-2027?
The median 12-month analyst price target for Actuate Therapeutics, Inc. is $8, with estimates ranging from $3 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ACTU stock a buy right now?
Of the 3 analysts covering Actuate Therapeutics, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Actuate Therapeutics, Inc. 39 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ACTU?
As at 21 Nov 2026, Actuate Therapeutics, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (83 of 100).
Will ACTU stock go up?
No one can know that. What the data says: the median 12-month target from 3 analysts is $8, and Ticker Nerd's factor model ranks Actuate Therapeutics, Inc. 39 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ACTU stock forecast for 2030?
No analyst covering Actuate Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ACTU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $10 over the next 12 months.
How has ACTU stock performed over the past year?
Actuate Therapeutics, Inc. returned -96.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Actuate Therapeutics, Inc. do?
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. Its lead program centers on elraglusib, a small-molecule GSK-3 inhibitor being studied in clinical trials for advanced solid tumors and certain pediatric cancers.
About Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers. Its lead program centers on elraglusib, a small-molecule GSK-3 inhibitor being studied in clinical trials for advanced solid tumors and certain pediatric cancers. The company’s work is aimed at targeting cancer pathways involved in tumor growth, survival, and resistance to standard treatments. Actuate Therapeutics also explores applications in cancer types and related disease areas where conventional options remain limited, positioning it within the oncology drug development segment of the healthcare market. Headquartered in Fort Worth, Texas, Actuate Therapeutics concentrates on advancing investigational medicines through early and mid-stage development, with a business model built around translational research, clinical testing, and potential future commercialization of targeted therapies.
CEO Mr. Daniel M. Schmitt · 12 employees · United States · https://actuatetherapeutics.com